Navigation Links
Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
Date:10/5/2007

Urologists at Thomas Jefferson University Hospital are studying whether a neo-bladder construct grown from a patients own cells can improve bladder function for adult spinal cord injury patients.

Jefferson is only one of six sites in the U.S. enrolling participants in this clinical trial for the lab-grown neo-bladder construct that will involve a total of 10 patients.

Its never been done in adults before, said primary investigator Patrick Shenot, M.D., instructor in Urology, Jefferson Medical College of Thomas Jefferson University, noting that a similar study is being conducted with children with spina bifida.

The neo-bladder constructs are being developed by Tengion, Inc. in their pilot manufacturing facility.

Each neo-bladder construct consists of a biodegradable scaffold seeded with urothelial and smooth muscle cells cultured in Tengions facility from the patients own bladder cells.

To participate in the study, a patient must be 18 to 65 years of age, have had a spinal cord injury for more than a year and diagnosed with a neurogenic bladder that is not adequately responding to medical therapy.

The urologist first performs a biopsy on the patient to retrieve the cells. The cells are then sent to Tengions manufacturing facility where they are grown in culture and then seeded onto a biodegradable scaffold in the shape of a bladder.

Then, the patient returns to hospital and the urologist will implant the neo-bladder construct in a procedure known as augmentation cystoplasty or bladder augmentation.

The neo-bladder is expected to continue to regenerate within the patient, using the bodys inherent regenerative capabilities, and if successful may result in improved bladder function, Dr. Shenot noted.

The field of regenerative medicine is anticipated to be an area of intense interest and expansion in the coming years, said Dr. Shenot.

While this first trial in adults is for patients with bladder control problems due to spinal cord injury, the possibilities for expansion into oncology related areas are promising, he said.


'/>"/>

Contact: Jeff Baxt
jeffrey.baxt@jefferson.edu
215-955-5507
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. Jefferson Virologists Coax HIV Out of Hiding
2. Jefferson researchers find nanoparticle shows promise in reducing radiation side effects
3. Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method
4. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
5. Jefferson researchers building a better rabies vaccine
6. Jefferson scientists identify gene mutation potentially involved in breast cancer initiation
7. Immune cell communication key to hunting viruses, Jefferson immunologists show
8. Jefferson researchers uncover new way nature turns genes on and off
9. Jefferson scientists find aging gene also protects against prostate cancer development
10. Jefferson scientists find high glucose before surgery raises risk of dangerous complications
11. Jefferson researchers discovery may change thinking on how viruses invade the brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: